Researchers have identified a key enzyme, PGM3, as a promising target to fight glioblastoma, the most aggressive and deadly type of brain tumor. This discovery, published in Science Advances, could lead to more effective treatments for this cancer, which currently has very few options.

PGM3 plays a critical role in the hexosamine synthesis pathway, which helps create the connection between sugars and fats (lipids) in cells. This process, known as lipid glycosylation, is essential for tumor growth. In the case of glioblastoma, this process allows the tumor to grow rapidly by linking sugar molecules to fats in the tumor cells. The researchers believe that by blocking PGM3, they can stop this process and reduce tumor growth, potentially eliminating glioblastoma cells.

Glioblastoma develops from glial cells in the brain and is notorious for its rapid growth and resistance to treatment. It is estimated that 15,000 people are diagnosed with glioblastoma each year. The current treatment options are limited, and patients typically survive only 12 to 16 months after diagnosis, despite undergoing aggressive treatments. This makes the search for new molecular targets for treatment urgently needed.

The research team, led by scientists from The Ohio State University Comprehensive Cancer Center, found that inhibiting PGM3 can disrupt the connection between sugar and fat creation in glioblastoma cells, leading to a decrease in tumor growth. This breakthrough gives hope for developing more effective therapies that could improve survival rates for patients with this deadly brain cancer.

The study was carried out in collaboration with scientists from France, the University of California-Los Angeles, University of California-Irvine, and University of Louisville. It is considered a significant step toward improving treatments for glioblastoma and other similar cancers. Start taking care of your brain at www.superbrainpower.org